Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. J.Molner AS's retained earnings for the quarter that ended in Dec. 2025 was €-6.18 Mil.
J.Molner AS's quarterly retained earnings
declined
from Dec. 2024 (€-6.31 Mil) to Jun. 2025 (€-7.72 Mil) but then
increased
from Jun. 2025 (€-7.72 Mil) to Dec. 2025 (€-6.18 Mil).
J.Molner AS's annual retained earnings
declined
from Dec. 2023 (€-3.87 Mil) to Dec. 2024 (€-6.31 Mil) but then
increased
from Dec. 2024 (€-6.31 Mil) to Dec. 2025 (€-6.18 Mil).
J.Molner AS (OTSE:MOLNR) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
J.Molner AS Retained Earnings Historical Data
* Premium members only.
The historical data trend for J.Molner AS's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
J.Molner AS (OTSE:MOLNR) has a Retained Earnings of €-6.18 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on J.Molner AS and its competitors.
Is J.Molner AS's Retained Earnings too high?
J.Molner AS's current Retained Earnings is €-6.18 Mil. Overall, J.Molner AS has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Retained Earnings compare to ZTS and UTHR?
J.Molner AS's Retained Earnings of €-6.18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on J.Molner AS and its competitors. J.Molner AS's current Retained Earnings is €-6.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.65, compared to a current price of €18.00 — trading 8.4% below its estimated fair value. The current Retained Earnings is €-6.18 Mil. J.Molner AS's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Retained Earnings is €-6.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.00 is trading 8.4% below its estimated GF Value™ of €19.65.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
Retained Earnings: €-6.18 Mil
GF Value™: €19.65 vs. price of €18.00 (8.4% below fair value)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
41GF Score
Get the complete analysis for OTSE:MOLNR
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
